Pathways’ Pick of the Week: DME Bid Program Languishes

article image
ARTICLE SUMMARY:

The Durable Medical Equipment Medicare Competitive Bidding Program is facing an uncertain future. Excerpted from Pathways’ Picks, February 10.

[For a complete roundup of medtech policy happenings that should be on your radar this week, deeper analysis of the sector, and a comprehensive inventory of global medtech policy documents check out Market Pathways. If you don’t subscribe, sign up for a free trial.]

A “Pivotal Bid Report” from CMS that was requested by stakeholders showed a wide variation in bid amounts and some steep rate increases tied to the latest cycle of the durable medical equipment (DME) Medicare Competitive Bidding Program. It adds more questions about the future of the program that is intended to reduce Medicare spending. The report followed an announcement by CMS in October that, after a two-year program suspension, its January 2021 DME bidding round was only going to accept bids for off-the-shelf back and knee braces. That does not include the other 13 DME product bidding categories, including CPAP and oxygen equipment. CMS said it did not achieve expected savings for those products based on its experience in prior rounds. “The future of Medicare's competitive bidding program for durable medical equipment appears to be up in the air,” Eric Assaraf, a health policy analyst with Cowen Washington Research Group, said in a February 5 note on the latest DME report. “What seems clear, though, is that Medicare's competitive bidding program is no longer the threat it once was to the DME industry.”

 

Excerpted from “Pathways’ Picks: Updates from China, Nomination Chatter, DigHealth Scrutiny,” Market Pathways, February 10, 2021.

 Trial MyStrategist.com and unlock 7-days of exclusive subscriber-only access to the medical device industry's most trusted strategic publications: MedTech Strategist & Market Pathways. For more information on our demographics and current readership click here.

Articles from David Filmore:

Regulatory & Reimbursement

Jeff Shuren on Novel Devices, MDUFA Talks, and the Toils of COVID

While CDRH is holding off on near-term strategic priority planning due to the overwhelming burden of COVID-19, center director Jeff Shuren is preaching the virtues of thinking big in the mid-and long-term. That means adopting the lessons of the pandemic response and retooling the device framework to meet the needs of evolving technologies. “We don’t think it is a time to stay complacent,” Shuren says in an interview with Market Pathways, just before user fee negotiations with industry begin.

Read Article